Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $444,091 | $281,594 | $202,129 | $402,710 |
| Dep. & Amort. | $88,662 | $84,856 | $57,480 | $6,639 |
| Deferred Tax | $0 | $34,506 | $0 | $0 |
| Stock-Based Comp. | $43,385 | $36,620 | $24,397 | $20,820 |
| Change in WC | -$136,270 | -$38,671 | -$110,486 | $2,571 |
| Other Non-Cash | $39,196 | -$10,334 | $66,590 | -$133,300 |
| Operating Cash Flow | $479,064 | $388,571 | $240,110 | $299,440 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$10,696 | -$15,294 | -$4,810 | -$1,457 |
| Net Acquisitions | $0 | $0 | -$999,120 | $0 |
| Inv. Purchases | $0 | -$292,911 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $211,296 | $0 | $0 |
| Other Inv. Act. | -$252,027 | $0 | $516,925 | -$404,832 |
| Investing Cash Flow | -$262,723 | -$96,909 | -$487,005 | -$406,289 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$13,483 | $624,547 | $415,811 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$250,000 | -$402,383 | -$200,002 | -$350,058 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $31,139 | $7,879 | -$62,174 | $12,112 |
| Financing Cash Flow | -$218,861 | -$407,987 | $362,371 | $77,865 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$2,520 | -$116,325 | $115,476 | -$28,984 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $118,370 | $234,695 | $119,219 | $148,203 |
| End Cash | $115,850 | $118,370 | $234,695 | $119,219 |
| Free Cash Flow | $468,368 | $373,277 | $235,300 | $297,983 |